Literature DB >> 16054479

Evaluation of acute risk for myocardial infarction in men treated with sildenafil citrate.

Murray A Mittleman1, Malcolm Maclure, Dale B Glasser.   

Abstract

Sexual intercourse is a rare trigger of acute myocardial infarction (MI). In the 2 hours after intercourse, the risk for MI is increased twofold to fourfold. However, there is limited information on the risk for MI after intercourse in men receiving treatment for erectile dysfunction. This study aimed to evaluate whether the use of sildenafil citrate in men with erectile dysfunction is associated with the triggering of acute MI. A self-matched case-crossover approach was used to evaluate the incidence of MI in men enrolled in 80 clinical trials of sildenafil at sites worldwide from 1993 to 2000. The risk for MI was assessed during 2 hazard periods: within 24 and within 6 hours after the ingestion of sildenafil. Relative risk was estimated using the Mantel-Haenszel estimator for sparse person-time data. A total of 69 MIs were observed during >11,000 person-years of exposure to sildenafil. The mean time between the last dose of sildenafil and the onset of MI was 14 +/- 2.9 days. The relative risk for MI was 0.80 (95% confidence interval [CI] 0.52 to 1.26) within 24 hours after taking sildenafil and 0.79 (95% CI 0.33 to 1.87) within 6 hours after taking sildenafil. In conclusion, these data indicate that sildenafil was not associated with short-term risk for MI and are consistent with the growing body of evidence that sildenafil use is not associated with an increased risk for cardiovascular events.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16054479     DOI: 10.1016/j.amjcard.2005.03.097

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

Review 1.  Sexual activity and ischemic heart disease.

Authors:  Richard A Lange; Glenn N Levine
Journal:  Curr Cardiol Rep       Date:  2014-02       Impact factor: 2.931

2.  Potential for bias in case-crossover studies with shared exposures analyzed using SAS.

Authors:  Shirley V Wang; Brent A Coull; Joel Schwartz; Murray A Mittleman; Gregory A Wellenius
Journal:  Am J Epidemiol       Date:  2011-05-03       Impact factor: 4.897

3.  Antidepressant prescriptions: an acute window for falls in the nursing home.

Authors:  Sarah D Berry; Yuqing Zhang; Lewis A Lipsitz; Murray A Mittleman; Daniel H Solomon; Douglas P Kiel
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-07-15       Impact factor: 6.053

Review 4.  Physical, psychological and chemical triggers of acute cardiovascular events: preventive strategies.

Authors:  Murray A Mittleman; Elizabeth Mostofsky
Journal:  Circulation       Date:  2011-07-19       Impact factor: 29.690

Review 5.  Erectile dysfunction in patients with cardiovascular disease.

Authors:  A J M Oude Ophuis; A A B Lycklama À Nijeholt
Journal:  Neth Heart J       Date:  2006-04       Impact factor: 2.380

Review 6.  Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date.

Authors:  Alan M Laties
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

7.  Post-marketing surveillance of ischaemic optic neuropathy in male veterans co-prescribed phosphodiesterase-5 inhibitors with organic nitrates or alpha-blockers.

Authors:  Dustin D French; Curtis E Margo
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

8.  Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy.

Authors:  L Gorkin; K Hvidsten; R E Sobel; R Siegel
Journal:  Int J Clin Pract       Date:  2006-04       Impact factor: 2.503

Review 9.  Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database.

Authors:  F Giuliano; G Jackson; F Montorsi; A Martin-Morales; P Raillard
Journal:  Int J Clin Pract       Date:  2009-11-09       Impact factor: 2.503

Review 10.  Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs.

Authors:  Dimitrios Terentes-Printzios; Nikolaos Ioakeimidis; Konstantinos Rokkas; Charalambos Vlachopoulos
Journal:  Nat Rev Cardiol       Date:  2021-07-30       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.